Literature DB >> 8620966

Peak inspiratory flow through Turbuhaler in acute asthma.

P H Brown1, A C Ning, A P Greening, A McLean, G K Crompton.   

Abstract

Efficient use of dry powder inhalers, such as Turbuhaler, is dependent on the generation of adequate inspiratory flow. It is not clear whether patients with acute asthma are able to generate adequate flow. Peak inspiratory flow (PIF) was measured through an empty Turbuhaler, and without this device, in 99 adults presenting to hospital with acute exacerbations of asthma. Where possible, patients were studied prior to nebulized bronchodilator therapy. Mean (SD) forced expiratory volume in one second (FEV1) was 1.2 (0.7) L, forced vital capacity (FVC) 2.1(1.0) L and peak expiratory flow (PEF) 199 (92) L.min-1. PIF without Turbuhaler was 152 (77) L.min-1 and correlated with PEF (r = 0.69). PIF through Turbuhaler was 60 (20) L.min-1 and weakly correlated with PEF (r = 0.35), and with PIF without Turbuhaler (r = 0.43). Two patients failed to generate the minimum inspiratory flow (30 L.min) required for efficient use of Turbuhaler; both recorded 26 L.min-1. Acute asthma is associated with considerable inspiratory, as well as expiratory airflow limitation. The relationship between inspiratory and expiratory airflow is not strong enough to predict whether patients with severe acute asthma will have difficulty using dry powder inhalers efficiently. Despite this, 98% of patients in this study generated inspiratory flow through Turbuhaler which would allow a therapeutically active amount of bronchodilator drug to be delivered to the airways.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8620966     DOI: 10.1183/09031936.95.08111940

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  11 in total

1.  Optical feedback training of inhalation with Autohaler and Turbuhaler in COPD patients.

Authors:  J Steier; T Trammer; R M Cloes; W Petro
Journal:  Lung       Date:  2003       Impact factor: 2.584

2.  Inhaler devices for asthma: do we follow the guidelines?

Authors:  F Child; S Davies; S Clayton; A A Fryer; W Lenney
Journal:  Arch Dis Child       Date:  2002-03       Impact factor: 3.791

3.  Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler.

Authors:  H Kaiser; D Aaronson; R Dockhorn; S Edsbäcker; P Korenblat; A Källén
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

Review 4.  Pharmacological factors that influence the choice of inhaled corticosteroids.

Authors:  S Edsbäcker
Journal:  Drugs       Date:  1999       Impact factor: 9.546

5.  Reduced Peak Inspiratory Effort through the Diskus((R)) and the Turbuhaler((R)) due to Mishandling is Common in Clinical Practice.

Authors:  Andrea S Melani; Letizia S Bracci; Marcello Rossi
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

6.  Comparative efficacy of terbutaline sulphate delivered by Turbuhaler dry powder inhaler or pressurised metered dose inhaler with Nebuhaler spacer in children during an acute asthmatic episode.

Authors:  S Drblik; G Lapierre; R Thivierge; J Turgeon; P Gaudreault; B Cummins-McManus; I Verdy; J Haddon; J Lee; S Spier
Journal:  Arch Dis Child       Date:  2003-04       Impact factor: 3.791

7.  In Vitro Flow Rate Dependency of Delivered Dose and Fine Particle Dose of Salmeterol/Fluticasone Propionate Easyhaler and Seretide Diskus with Patient Flow Rates Collected in a Randomized Controlled Trial.

Authors:  Rain Jõgi; Satu Lähelmä; Mikko Vahteristo; Anita Happonen; Jussi Haikarainen
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2018-10-09       Impact factor: 2.849

8.  Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study.

Authors:  Wahida Azouz; Philip Chetcuti; Harold Hosker; Dinesh Saralaya; Henry Chrystyn
Journal:  BMC Pulm Med       Date:  2015-05-01       Impact factor: 3.317

Review 9.  What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape.

Authors:  Federico Lavorini; Christer Janson; Fulvio Braido; Georgios Stratelis; Anders Løkke
Journal:  Ther Adv Respir Dis       Date:  2019 Jan-Dec       Impact factor: 4.031

10.  Patients with asthma or chronic obstructive pulmonary disease (COPD) can generate sufficient inspiratory flows via Easyhaler® dry powder inhaler: a pooled analysis of two randomized controlled trials.

Authors:  L Pekka Malmberg; Anna S Pelkonen; Ville Vartiainen; Mikko Vahteristo; Satu Lähelmä; Rain Jõgi
Journal:  J Thorac Dis       Date:  2021-02       Impact factor: 3.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.